Back to top
more

Doximity (DOCS)

(Real Time Quote from BATS)

$58.29 USD

58.29
1,283,357

-0.01 (-0.02%)

Updated Aug 5, 2025 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Doximity (DOCS) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.

Zacks Equity Research

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSML

Zacks Equity Research

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSML

Zacks Equity Research

Doximity (DOCS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Company News for May 20, 2024

by Zacks Equity Research

Companies in The News Are: RBC,FLO,DOCS,GME

Zacks Equity Research

Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 25% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ahead of Doximity (DOCS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Organon (OGN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 25.77% and 3.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity

by Zacks Equity Research

Elevance Health, Medpace and Doximity are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Industry Stocks to Buy as Nursing Market Booms

by Urmimala Biswas

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most. However, staffing shortages continue to put brakes on growth.

Zacks Equity Research

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSML

Zacks Equity Research

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSML

Zacks Equity Research

SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SGRY vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Down -6.99% in 4 Weeks, Here's Why You Should You Buy the Dip in Doximity (DOCS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Doximity (DOCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

All You Need to Know About Doximity (DOCS) Rating Upgrade to Buy

by Zacks Equity Research

Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

ICLR vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

ICLR vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Compared to Estimates, Doximity (DOCS) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix

by Zacks Equity Research

Medpace, Doximity and Biodesix have been highlighted in this Industry Outlook article.

Zacks Equity Research

Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?

by Zacks Equity Research

Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy as Industry Trends Improve

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend.

Zacks Equity Research

ICLR or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ICLR vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.